U.S. Markets open in 7 hrs 53 mins

Nascent Biotech, Inc. (NBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0787+0.0008 (+1.03%)
At close: 3:25PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0779
Open0.0807
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0740 - 0.0807
52 Week Range0.0437 - 0.2780
Volume81,180
Avg. Volume434,447
Market Cap7.561M
Beta (5Y Monthly)-2.50
PE Ratio (TTM)N/A
EPS (TTM)-0.0760
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

    SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that patients have been enrolled and initial dosing has begun in the Company's landmark Phase I trial to evaluate Pritumumab ("PTB") as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases.

  • ACCESSWIRE

    Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

    SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Company's lead Monoclonal Antibody (Mab) therapeutic asset, as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases.

  • ACCESSWIRE

    Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier

    SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce that the Company has officially received allowance for a "Method-of-Use" patent by the US Patent and Trademark Office ("USPTO") for their primary asset, Pritumumab ("PTB").